Antiepileptic drugs are therapies approved to treat patients with epilepsy, a brain disorder in which clusters of nerve cells signal abnormally, which can lead to seizures. These seizures are incidents that occur when group of nerve cells or neurons in brain sends wrong signals. Patients suffering from epilepsy may complain about strange emotions and sensations or they may behave strangely. Epilepsy is the fourth most common brain disorder affecting people of all ages. The causes of epilepsy are undetermined however major risk factors involved include brain injury, brain tumor, stroke, and substance use disorders. For the treatment of epilepsy, antiepileptic medicines (AEDs) are prescribed, preference of the drug depending on the age of the patient, type of seizures to be treated, seriousness of the seizures, and part of the brain involved. Alcoholism, smoking, changing lifestyle and rising geriatric population are the major factor driving the antiepileptic market.

The market for antiepileptic drugs is broadly classified on the basis of first generation antiepileptic drugs and second generation antiepileptic drugs and pipeline drugs. First generation antiepileptic drugs consists of Valproate (Depakote), Oxycarbazepine ((Trileptal), Carbamazepine (Carbatrol), Phenobarbital (Luminal), Primidone (Mysoline), Ethosuximide (Zarontin), Topiramate (Topamax) Phenytoin (Dilantin, Phenytek). Second generation antiepileptic drugs consist of different mechanism of action than the first generation drugs. These consists of Lamotrigine (Lamictal), Pregabalin (Lyrica), Eslicarbazepine acetate Zonisamide (Zonegran), Lacosamide (Vimpat), Levetiracetam (Keppra), (Aptiom/Zebinix),  Perampanel (Fycompa), Rufinamide (Banzel/Inovelon), Ezogabine/retigabine (Trobalt/Potiga),. First generation antiepileptic drugs majorly carbamazepine, valproate, phenytoin and oxycarbazepine are dominating the epilepsy therapeutics market. However, second generation AEDs such as levetiracetam, zonisamide and lacosamide are slowly overtaking the antiepileptic drugs market due to its improved tolerability and efficacy.

The pipeline for antiepileptic drugs has been segmented on different phases. The drugs in the phase III of the pipeline include Brivaracetam (UCB Pharma Ltd), Ganaxolone (Marinus Pharmaceuticals), USL261 (Upsher Smith Laboratories, Inc.), Perampanel (Eisai Co) and YKP3089 (SK Life Sciences) and others. The phase I and II of the pipeline drugs include Buspirone, Everoline, UCB0942 (PPSI), Lacosamide, GWP42006, TAK-932 and others. All this drugs are currently under clinical trials and it is expected that these drugs will prove beneficial for epilepsy therapeutics market.

Geographically, North America dominates the global antiepileptic drugs market followed by Europe majorly due to the extensive research and development activities in the neurology and the presence of pharmaceutical industries in the region. Epilepsy affects approximately 2.5 million people in the United States, and results in an estimated annual cost of approximately $15.5 billion in healthcare. Three new antiepileptic drugs have been approved in U.S. since 2012 including ezogabine/retigabine, perampanel and eslicarbazepine acetate. Continuous increase in uptake of second generation antiepileptic drugs is also driving the antiepileptic drugs market in North America and Europe. Asia-Pacific is also increasing constantly in the antiepileptic drugs market mainly due to the high prevalence of epilepsy in India and China, increased penetration due to better market access options in China and expected approval of drugs with novel mechanisms are some of the factors responsible for expanding the epilepsy therapeutics market in the Asia-Pacific region. Latin America is also a growing market for antiepileptic drugs due to developing healthcare expenditure and high prevalence rate of epilepsy in the region.

Some of the major players in epilepsy therapeutics market include Abbott Laboratories, Cephalon, Inc, GlaxoSmithKline plc,., Johnson & Johnson, Novartis AG, Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A. and UCB Pharma Ltd.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Antiepileptic Drugs Market

Pre Book